Sign in

NCT07065383Recruiting

Rebalancing the Fat Content of the Heart and Muscles

Intramyocellular Lipid Compartments After Glucagon-like Peptide 1 Receptor Agonist Therapy in Type 2 Diabetes - Rebalancing the Fat Content of the Heart and Muscles

Source: ClinicalTrials.gov · Last updated 30 Apr 2026

Brief summary (registry, in English)

Traditional diabetes therapies focus on improving blood sugar control. However, many studies show that this may not be enough. New treatments focusing on weight loss have heralded better results. One of these treatments is Semaglutide and the investigators wish to examine its effects further in this study. The investigators propose to investigate what happens to the fat inside the heart and the leg muscles.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
60 (estimated)
First submitted
24 Jun 2025
Start date
1 Aug 2025
Primary completion date
31 Jul 2028
Lead sponsor
University of Aberdeen
NCT number
NCT07065383

What you commit to

  • Study type: Interventional
  • Planned participants: 60
  • From 1 Aug 2025 to the primary completion date, 31 Jul 2028
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Any previously unknown cardiac condition other than mild valvular disease
  • Patients with any dietary habits that may interfere with the investigation (for example high fat vegan diets, as we know form prior research that they have very different intramyocellular fat storage compared to those on no dietary preferences)

Other illness

  • Any history of known coronary artery disease (including myocardial infarction and myocardial infarction with normal coronary arteries)
  • Any relevant or untreated endocrine condition (i.e. Cushings)
  • Patients with any history of any medical or surgical condition that in the judgement of the investigators may interfere with the exercise regime (i.e. peripheral vascular disease, arthritis), fatty acids metabolism (i.e. lipid storage diseases) or may compromise the safety of the participant (i.e. neurological syndromes for whom an intense exercise program could result in musculo-skeletal injury or accidents due to loss of balance).
  • Patients with a sensitivity to Semaglutide (known hypersensitivity, diabetic retinopathy, pregnancy, history of pancreatitis or history of any cancer)
  • Significant asthma or pulmonary disease

Lab values

  • Patients on any other medication known to influence glucose or fatty acids metabolism (niacin, omega-3 fatty acids, other glucagon-like peptide-1 receptor agonists)

Other

  • Impaired renal function (defined as estimated glomerular filtration rate of less than 30 mL/min/1.73m2)
  • Blood pressure of more than 180/100 mmHg
  • Participants unable to cycle on the ergometer
  • Unable to perform exercise testing (e.g. prosthetic limbs)
  • Pregnancy, breastfeeding or considering pregnancy.
  • Patients who have recently had gastrointestinal contrast or radionuclides
  • Inability to lie flat or remain motionless for scanning procedures
  • Patients whose girth size cannot allow them to fit in the magnetic resonance scanner (there is no set location to measure as this is different for everyone, but we have a plastic hoop that can be fitted around the largest circumference to check the fit)
  • Subjects who are not able to engage into a physical training regime or feel that they do not have the interest or sustained motivation to follow one.
  • Participants currently enrolled in other interventional clinical research
  • Participants not able to understand written or verbal English

Who the study is looking for

  • Patients with a confirmed diagnosis of type 2 diabetes established in the previous 10 years between the ages of 20 and 75
  • HbA1c ≥ 53 mmol/mol (7%) typically on diet and/or metformin/sulphonylureas (and/or sodium-glucose cotransporter-2 inhibitors, Dipeptidyl peptidase 4 inhibitors, thiazolidinediones, but not on insulin)
  • Patients who do not meet the WHO recommendations on physical activity (≤150 minutes per week) of moderate-vigorous physical activity (MVPA)
  • Patients who have a BMI of ≥27 but with a body weight of less than 140kgs due to limitations of the scanner table weight limit
  • Current or recent (within 3 months) eGFR \>30 mL/min/1.73m2)
  • Able to understand written and spoken English

Age in the registry: 20 years to 75 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Cardiac Research Office, Aberdeen Royal Infirmary
Coordinator of this site? Confirm its status
AberdeenUnited KingdomRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.